Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic pheochromocytoma and paraganglioma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial has compared radionuclide therapy with drugs or defined their order.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Azedra's withdrawal leaves MIBG-avid, somatostatin-receptor-negative patients without a radionuclide option in many countries.
Catecholamine crises during treatment remain dangerous.
The disease is too rare and too slow for conventional trial designs.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Progression-free survival at 12 months 36 percent with sunitinib against 19 percent with placebo, meeting the primary endpoint of the first randomised trial in the disease.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Alpha-blockade with beta-blockade added second; metyrosine for refractory symptoms; blockade before every procedure; bone-protective agents for skeletal metastases.